Drugs for Psychiatric Disorders | The Medical Letter Inc.

Treatment Guidelines from The Medical Letter

FROM
ISSUE

130

June 1, 2013

View Complete Issue Table of Contents 2019

Drugs for Psychiatric Disorders

Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article.

Drugs for Psychiatric Disorders

June 1, 2013 (Issue: 130)

Superseded by The Medical Letter "Drugs for Depression" - Issue 1691, December 11, 2023
Superseded by The Medical Letter "Drugs for Bipolar Disorder" - Issue 1699, April 1, 2024
Superseded by The Medical Letter "Drugs for Psychotic Disorders" - Issue 1510, December 19, 2016

Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) can be used for many of them as well. Electroconvulsive therapy...more

Show References Hide References

1. Extended-release trazodone (Oleptro) for depression. Med Lett Drugs Ther 2010; 52:91.

2. Vilazodone (Viibryd) – a new antidepressant. Med Lett Drugs Ther 2011; 53:53.

3. V Rabenda et al. Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants. Bone 2012; 51:674.

4. Citalopram (Celexa) and QT-interval prolongation. Med Lett Drugs Ther 2012; 54:71.

5. VM Castro et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013; 346:f288.

6. SE Hetrick et al. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2012; (11):CD004851.

7. EW Boyer and M Shannon. The serotonin syndrome. N Engl J Med 2005; 352:1112.

8. KL Wisner et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166:557.

9. N Lund et al. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009; 163:949.

10. S Gentile. On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome. CNS Spectr 2010; 15:167.

11. CD Chambers et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354:579.

12. A Bérard et al. Paroxetine use during pregnancy and perinatal outcomes including types of cardiac malformations in Quebec and France: A short communication. Curr Drug Saf 2012; 7:207.

13. A Einarson et al. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 2009; 54:242.

14. M Tuccori et al. Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update. Postgrad Med 2010; 122:49.

15. S Alwan et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356:2684.

16. C Louik et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356:2675.

17. O Stephansson et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013; 309:48.

18. LH Pedersen et al. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010; 125:e600 (epub Feb 22).

19. KR Connolly and ME Thase. If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011; 71:43.

20. AJ Rush et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354:1231.

21. Adjunctive antipsychotics for major depression. Med Lett Drugs Ther 2011; 53:74.

22. BM Wright et al. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. Pharmacotherapy 2013; 33:344.

23. PE Holtzheimer and HS Mayberg. Neuromodulation for treatment-resistant depression. F1000 Med Rep 2012; 4:22.

24. Repetitive transcranial magnetic stimulation (TMS) for medication-resistant depression. Med Lett Drugs Ther 2009; 51:12.

25. Vagus nerve stimulation for depression. Med Lett Drugs Ther 2005; 47:50.

26. JR Geddes and DJ Miklowitz. Treatment of bipolar disorder. Lancet 2013; 381:1672.

27. ME Thase and T Denko. Pharmacotherapy of mood disorders. Annu Rev Clin Psychol 2008; 4:53.

28. L Tondo and RJ Baldessarini. Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients. Epidemiol Psychiatr Soc 2009; 18:179.

29. LA Smith et al. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord 2010; 122:1.

30. YW Shi et al. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502? Basic Chem Pharmacol Toxicol 2012; 111:58.

31. P Cacoub et al. The DRESS syndrome: a literature review. Am J Med 2011; 124:588.

32. SH Joe et al. Feasibility of a slower lamotrigine titration schedule for bipolar depression: a naturalistic study. Int Clin Psychopharmacol 2009; 24:105.

33. FDA Drug Safety Communication: valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. Available at www.fda.gov. Accessed May 12, 2013.

34. S Gentile. Antipsychotic therapy during early and late pregnancy. Asystematic review. Schizophr Bull 2010; 36:518.

35. RJ Baldessarini. Chemotherapy in Psychiatry, third edition. New York: Springer Press 2013.

36. S Leucht et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2012; 5:CD008016.

37. S Leucht et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373:31.

38. L Hartling et al. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med 2012;157:498.

39. HY Meltzer et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60:82.

40. J Tiihonen et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374:620.

41. S Leucht et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166:152.

42. Asenapine (Saphris) sublingual tablets for schizophrenia and bipolar disorder. Med Lett Drugs Ther 2010; 52:9.

43. Iloperidone (Fanapt) - another second-generation antipsychotic. Med Lett Drugs Ther 2010; 52:13.

44. Lurasidone (Latuda) for schizophrenia. Med Lett Drugs Ther 2011; 53:13.

45. R Emsley et al. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry Jan 2013 (epub ahead of print).

46. O Freudenreich and JP McEvoy. Optimizing outcome with antipsychotic treatment in first-episode schizophrenia: balancing efficacy and side effects. Clin Schizophr Relat Psychoses 2012; 6:115.

47. CU Correll and EM Schenk. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21:151.

48. R Liperoti et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry 2009; 70:1340.

49. J Fitzsimons et al. A review of clozapine safety. Expert Opin Drug Saf 2005; 4:731.

50. KJ Ronaldson et al. Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases. Schizophr Res 2011; 128:161.

51. R Emsley et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008; 23:343.

52. FW Fraunfelder. Twice-yearly exams unnecessary for patients taking quetiapine. Am J Ophthalmol. 2004; 138:870.

53. CU Pae. A review of the safety and tolerability of aripiprazole. Expert Opin Drug Saf 2009; 8:373.

54. J Weber and PL McCormack. Asenapine. CNS Drugs 2009; 23:781.

55. JM Kane et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008; 28(2 Suppl 1):S29.

56. L Citrome. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011; 65:189.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.